Johnson & Johnson $JNJ Shares Purchased by Danica Pension Livsforsikringsaktieselskab

Key Points

• Danica Pension increased its Johnson & Johnson stake by 21.5% in the second quarter, purchasing 37,287 additional shares to hold 210,735 shares valued at approximately $53.5 million.
• Institutional investors and hedge funds own 69.55% of JNJ, while insiders have sold 63,972 shares worth $16.25 million over the past three months.
• Analysts maintain a generally positive outlook, with JNJ receiving a “Moderate Buy” consensus rating and an average price target of $268.22; the company also reported quarterly earnings and revenue above expectations and pays a $1.34 quarterly dividend.

Danica Pension Livsforsikringsaktieselskab grew its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 21.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 210,735 shares of the company's stock after purchasing an additional 37,287 shares during the period. Johnson & Johnson makes up about 0.9% of Danica Pension Livsforsikringsaktieselskab's holdings, making the stock its 28th biggest position. Danica Pension Livsforsikringsaktieselskab's holdings in Johnson & Johnson were worth $53,520,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of JNJ. Silver Coast Investments LLC grew its holdings in Johnson & Johnson by 3.8% during the second quarter. Silver Coast Investments LLC now owns 1,066 shares of the company's stock worth $271,000 after acquiring an additional 39 shares during the period. Townsend Asset Management Corp NC ADV lifted its holdings in Johnson & Johnson by 0.6% in the second quarter. Townsend Asset Management Corp NC ADV now owns 6,418 shares of the company's stock valued at $1,630,000 after acquiring an additional 39 shares during the period. Sierra Capital LLC boosted its position in shares of Johnson & Johnson by 0.5% during the 4th quarter. Sierra Capital LLC now owns 8,144 shares of the company's stock worth $1,685,000 after purchasing an additional 41 shares in the last quarter. Beaird Harris Wealth Management LLC grew its stake in shares of Johnson & Johnson by 1.8% during the 4th quarter. Beaird Harris Wealth Management LLC now owns 2,422 shares of the company's stock worth $501,000 after purchasing an additional 42 shares during the period. Finally, Ballast Advisors LLC increased its holdings in shares of Johnson & Johnson by 1.2% in the 1st quarter. Ballast Advisors LLC now owns 3,598 shares of the company's stock valued at $879,000 after purchasing an additional 42 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Elizabeth Forminard sold 15,918 shares of the firm's stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the completion of the transaction, the executive vice president owned 16,994 shares of the company's stock, valued at approximately $4,367,458. This trade represents a 48.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Jennifer L. Taubert sold 15,000 shares of the company's stock in a transaction on Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the sale, the executive vice president owned 194,451 shares in the company, valued at $51,210,615.36. This represents a 7.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 63,972 shares of company stock worth $16,245,605. 0.16% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms recently commented on JNJ. HSBC set a $290.00 price objective on shares of Johnson & Johnson and gave the stock a "buy" rating in a report on Monday, July 6th. TD Cowen lifted their price target on shares of Johnson & Johnson from $250.00 to $300.00 and gave the company a "buy" rating in a research report on Monday, July 13th. Citigroup boosted their price target on Johnson & Johnson from $285.00 to $298.00 and gave the stock a "buy" rating in a research note on Wednesday, July 8th. The Goldman Sachs Group restated a "buy" rating and issued a $282.00 price target on shares of Johnson & Johnson in a report on Thursday, July 16th. Finally, Johnson Rice reaffirmed a "buy" rating on shares of Johnson & Johnson in a research note on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson has an average rating of "Moderate Buy" and an average target price of $268.22.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson continues to attract attention as a defensive, income-oriented healthcare holding. Commentary highlights the company’s history of maintaining and increasing dividends through recessions, which may support demand from long-term and retirement-focused investors. Two Recessions Couldn’t Stop These 4 Healthcare Stocks From Raising Dividends
• Positive Sentiment: An article reviewing J&J’s investments in 15 biotech and medtech companies points to potential strategic value and future upside from its investment portfolio, although these holdings are not currently a major earnings driver. Johnson & Johnson Owns Stakes in 15 Stocks. Here’s the Best of the Bunch.
• Neutral Sentiment: J&J will hold a conference call on October 13 to discuss third-quarter results. Chief Executive Officer Joaquin Duato, Chief Financial Officer Joseph Wolk, and other executives will participate. The event could provide a catalyst through updated guidance, pharmaceutical sales trends, and management commentary, but it does not change current fundamentals. Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
• Neutral Sentiment: Recent commentary compares JNJ’s performance with the consumer-staples sector and highlights its exposure to artificial-intelligence-related investments. These themes may improve investor visibility, but neither represents a new company announcement or near-term earnings catalyst. Johnson & Johnson Stock: Is JNJ Outperforming the Consumer Staples Sector?

Johnson & Johnson Stock Performance

Shares of JNJ opened at $265.79 on Tuesday. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The stock has a market cap of $640.53 billion, a P/E ratio of 30.80, a PEG ratio of 2.56 and a beta of 0.24. The company has a 50-day moving average of $259.57 and a two-hundred day moving average of $244.17. Johnson & Johnson has a 12-month low of $173.33 and a 12-month high of $276.47.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. During the same period in the prior year, the business earned $2.77 earnings per share. The company's quarterly revenue was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, research analysts predict that Johnson & Johnson will post 11.61 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be issued a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date is Tuesday, August 25th. Johnson & Johnson's dividend payout ratio is 62.11%.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source